Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab Combined With Radiotherapy for Older Patients With Esophageal Cancer
NCT01463605Phase 2Completed
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Jun 2011
- Primary completion
- Dec 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nimotuzumab in esophageal cancer, sponsored by Chinese Academy of Medical Sciences. Started Jun 2011; status: completed.
02
Drugs
nimotuzumab
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT01463605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01463605.